{
    "ticker": "GKOS",
    "name": "Glaukos Corporation",
    "description": "Glaukos Corporation is a pioneering medical technology company focused on the development and commercialization of transformative therapies for the treatment of glaucoma, one of the leading causes of blindness worldwide. Founded in 1998 and headquartered in San Clemente, California, Glaukos is dedicated to providing innovative solutions that improve patient outcomes and enhance the quality of life for those affected by ocular diseases. The company's flagship product, the iStent, is a minimally invasive device designed to lower intraocular pressure in patients with glaucoma. This breakthrough technology represents a significant advancement in the treatment landscape, allowing for a less invasive option compared to traditional surgical procedures. Glaukos continues to expand its product portfolio, including additional minimally invasive glaucoma surgical (MIGS) devices and sustained-release drug delivery systems aimed at improving medication adherence. With a strong commitment to research and development, Glaukos is at the forefront of innovation in ophthalmology, collaborating with healthcare professionals to address unmet needs in glaucoma care. The company aims to revolutionize the standard of care for glaucoma patients while driving growth and improving shareholder value.",
    "industry": [
        "Medical Devices",
        "Healthcare"
    ],
    "headquarters": "San Clemente, California, USA",
    "founded": "1998",
    "website": "https://www.glaukos.com",
    "ceo": "Thomas Burns",
    "social_media": {
        "twitter": "https://twitter.com/glaukos",
        "linkedin": "https://www.linkedin.com/company/glaukos-corporation/"
    },
    "investor_relations": "https://investors.glaukos.com",
    "key_executives": [
        {
            "name": "Thomas Burns",
            "position": "CEO"
        },
        {
            "name": "David M. B. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Minimally Invasive Glaucoma Surgery",
            "products": [
                "iStent",
                "iStent inject"
            ]
        },
        {
            "category": "Sustained-Release Drug Delivery",
            "products": [
                "Durysta"
            ]
        }
    ],
    "seo": {
        "meta_title": "Glaukos Corporation | Innovative Glaucoma Therapies",
        "meta_description": "Explore Glaukos Corporation, a leader in innovative glaucoma treatments. Learn about their groundbreaking products and commitment to improving patient care.",
        "keywords": [
            "Glaukos",
            "Glaucoma Treatment",
            "Ophthalmology",
            "Medical Devices",
            "MIGS",
            "iStent"
        ]
    },
    "faq": [
        {
            "question": "What is Glaukos known for?",
            "answer": "Glaukos is known for its innovative therapies for glaucoma, particularly its minimally invasive surgical devices."
        },
        {
            "question": "Who is the CEO of Glaukos?",
            "answer": "Thomas Burns is the CEO of Glaukos Corporation."
        },
        {
            "question": "Where is Glaukos headquartered?",
            "answer": "Glaukos is headquartered in San Clemente, California, USA."
        },
        {
            "question": "What are Glaukos's main products?",
            "answer": "Glaukos's main products include the iStent and Durysta."
        },
        {
            "question": "When was Glaukos founded?",
            "answer": "Glaukos was founded in 1998."
        }
    ],
    "competitors": [
        "ALGN",
        "EYES",
        "RXDX"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "GILD",
        "BIIB"
    ]
}